Docket No. SPO-103 Serial No. 09/142,524

Page 17, line 8: After "KSMKVTVAFNQFGPN" please insert -- (SEQ ID NO. 9)--.

<u>Page 17, line 11</u>: After "EEYLILSARDVLAVVSKRRMKVTVAFNQFGPN" please insert --(SEQ ID NO. 10)--.

Page 40, line 23: After "FIKRVSNVI" please insert -- (SEQ ID NO. 7)--.

Page 41, line 5: After "IFSKNLNIKLNMPLYIAGNK" please insert --, SEQ ID NO. 11--.

Page 41, line 7: After "SSGKNEGTNIYNNNEAFKVE" please insert --, SEQ ID NO. 12--.

Page 41, line 8: After "'FIKRVSNVI'" please insert -- (SEQ ID NO. 7)--.

Page 42, line 12: After "(VFIKRVSNVIIHG" please insert --, SEQ ID NO. 13--.

Page 42, line 24: After "'FIKRVSNVI" please insert -- (SEQ ID NO. 7)--.

Page 43, line 16: After "'SIKRVSNVI'" please insert (SEQ ID NO. 14)--.

In the Claims

Please amend the following claim:

Claim 1 (amended):

A peptide-based immunotherapeutic agent comprising [an effective amount of] a multiepitope peptide which is a linear polypeptide molecule comprising <u>at least two</u> different T cell epitope [regions] <u>peptides that are derived from two or more different allergen molecules and are</u> joined to each other <u>via a peptide bond in an amount effective to prevent or treat allergic symptoms</u> of a patient sensitive to the allergens, wherein